Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas

被引：66

作者：

Triebels, VHJM

Taphoorn, MJB

Brandes, AA

Menten, J

Frenay, M

Tosoni, A

Kros, JM

Biemond-ter Stege, E

Enting, RH

Allgeier, A

van Heuvel, I

van den Bent, MJ

机构：

[1] Erasmus Univ Hosp Rotterdam, Dr Daniel den Hoed Canc Ctr, Erasmus MC, Dept Neurooncol, NL-3008 AE Rotterdam, Netherlands

[2] Erasmus Univ Hosp Rotterdam, Dr Daniel den Hoed Canc Ctr, Erasmus MC, Dept Pathol, NL-3008 AE Rotterdam, Netherlands

[3] Canisius Wilhelmina Hosp, Nijmegen, Netherlands

[4] Univ Med Ctr Utrecht, Utrecht, Netherlands

[5] Univ Hosp Padova, Dept Med Oncol, Padua, Italy

[6] Univ Hosp Gasthuisberg, Dept Radiotherapy Oncol, B-3000 Louvain, Belgium

[7] Ctr Antoine Lacassagne, F-06054 Nice, France

[8] EORTC DataCtr, Brussels, Belgium

来源：

NEUROLOGY | 2004年 / 63卷 / 05期

关键词：

D O I：

10.1212/01.WNL.0000137049.65631.DB

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma. The genotype of the tumors was assessed with fluorescent in situ hybridization with locus specific probes for the region 1p36. Four of the 24 patients responded (17%). Fifty percent of patients were still free from progression at 6 months and 21% were free from progression at 12 months. Although a clear relation existed between loss of 1p and response to temozolomide chemotherapy, this relation was absent in salvage PCV chemotherapy.

引用

页码：904 / 906

页数：3

共 10 条

[1] CHEMOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIOMA [J].

CAIRNCROSS, G ;

MACDONALD, D ;

LUDWIN, S ;

LEE, D ;

CASCINO, T ;

BUCKNER, J ;

FULTON, D ;

DROPCHO, E ;

STEWART, D ;

SCHOLD, C ;

WAINMAN, N ;

EISENHAUER, E .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) :2013-2021

[2] Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy [J].

Chinot, OL ;

Honore, S ;

Dufour, H ;

Barrie, M ;

Figarella-Branger, D ;

Muracciole, X ;

Braguer, D ;

Martin, PM ;

Grisoli, F .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (09) :2449-2455

[3]

Ino Y, 2001, CLIN CANCER RES, V7, P839

[4] RESPONSE CRITERIA FOR PHASE-II STUDIES OF SUPRATENTORIAL MALIGNANT GLIOMA [J].

MACDONALD, DR ;

CASCINO, TL ;

SCHOLD, SC ;

CAIRNCROSS, JG .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) :1277-1280

[5] Salvage chemotherapy for oligodendroglioma [J].

Peterson, K ;

Paleologos, N ;

Forsyth, P ;

Macdonald, DR ;

Cairncross, JG .

JOURNAL OF NEUROSURGERY, 1996, 85 (04) :597-601

[6] Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy [J].

van den Bent, MJ ;

Kros, JM ;

Heimans, JJ ;

Pronk, LC ;

van Groeningen, CJ ;

Krouwer, HGJ ;

Taphoorn, MJB ;

Zonnenberg, BA ;

Tijssen, CC ;

Twijnstra, A ;

Punt, CJA ;

Boogerd, W .

NEUROLOGY, 1998, 51 (04) :1140-1145

[7] Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972 [J].

van den Bent, MJ ;

Chinot, O ;

Boogerd, W ;

Marques, JB ;

Taphoorn, MJB ;

Kros, JM ;

van der Rijt, CCD ;

Vecht, CJ ;

De Beule, N ;

Baron, B .

ANNALS OF ONCOLOGY, 2003, 14 (04) :599-602

[8] Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group study 26971 [J].

van den Bent, MJ ;

Taphoorn, MJB ;

Brandes, AA ;

Menten, J ;

Stupp, R ;

Frenay, M ;

Chinot, O ;

Kros, JM ;

van der Rijt, CCD ;

Vecht, CJ ;

Allgeier, A ;

Gorlia, T .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) :2525-2528

[9] Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features [J].

van den Bent, MJ ;

Looijenga, LHJ ;

Langenberg, K ;

Dinjens, W ;

Graveland, W ;

Uytdewilligen, L ;

Smitt, PAS ;

Jenkins, RB ;

Kros, JM .

CANCER, 2003, 97 (05) :1276-1284

[10] Temozolomide chemotherapy in recurrent oligodendroglioma [J].

van den Bent, MJ ;

Keime-Guibert, F ;

Brandes, AA ;

Taphoorn, MJB ;

Kros, JM ;

Eskens, FALM ;

Carpentier, AF .

NEUROLOGY, 2001, 57 (02) :340-342

← 1 →